Back to Search
Start Over
Low-dose aspirin use and risk of head and neck cancer-A Danish nationwide case-control study.
- Source :
-
British journal of clinical pharmacology [Br J Clin Pharmacol] 2021 Mar; Vol. 87 (3), pp. 1561-1567. Date of Electronic Publication: 2020 Aug 14. - Publication Year :
- 2021
-
Abstract
- Results concerning a potential preventive effect of aspirin on head and neck cancer (HNC) are conflicting. We examined the association between low-dose aspirin use and HNC risk overall and by degree of human papillomavirus association in a nested case-control study using nationwide registries. Cases (n = 12 389) were all Danish residents diagnosed with primary HNC (2000-2015). Age- and sex-matched population controls (n = 185 835) were selected by risk-set-sampling. Using conditional logistic regression, we estimated multivariable-adjusted odds ratios and 95% confidence intervals for HNC associated with low-dose aspirin use (≥2 prescriptions). No association was observed between low-dose aspirin ever-use and overall HNC (odds ratio: 1.03, 95% confidence interval: 0.97-1.10). Estimates remained neutral according to patterns of use. Low-dose aspirin use appeared to slightly decrease HNC risk among the eldest (71-84 y), independently of human papillomavirus association, while slightly increase HNC risk among younger age groups (30-60, 61-70 y), driven by an increased risk of oral cancer. However, no consistent patterns in risk estimates were found according to duration and consistency of low-dose aspirin use in the age-stratified analyses.<br /> (© 2020 The British Pharmacological Society.)
Details
- Language :
- English
- ISSN :
- 1365-2125
- Volume :
- 87
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- British journal of clinical pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 32737902
- Full Text :
- https://doi.org/10.1111/bcp.14502